<DOC>
	<DOCNO>NCT00004046</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DX-8951f treat woman metastatic breast cancer respond previous therapy .</brief_summary>
	<brief_title>Chemotherapy Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity DX-8951f woman metastatic adenocarcinoma breast fail prior therapy anthracycline taxane . II . Evaluate quantitative qualitative toxicity drug patient . III . Evaluate pharmacokinetics drug patient . OUTLINE : Patients receive DX-8951f IV 30 minute daily 5 day . Courses repeat every 21 day . Treatment continue absence unacceptable toxicity disease progression . Patients follow every 3 month death . PROJECTED ACCRUAL : A total 12-37 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma breast Prior treatment anthracycline ( e.g. , doxorubicin epirubicin ) taxane ( e.g. , paclitaxel docetaxel ) either adjuvant therapy advance disease Bidimensionally measurable disease Sentinel lesions must outside prior radiation port No resect disease stage IV evaluable disease No brain metastasis leptomeningeal disease No symptomatic lymphangitic pulmonary metastasis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Hemoglobin least 9.0 g/dL Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Neurologic : No history exist grade 34 peripheral neuropathy etiology Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No allergy camptothecin derivatives No concurrent serious infection No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No overt psychosis , mental disability , incompetence No life threaten disease PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy No prophylactic colony stimulate factor prevent neutropenia ( except neutropenia fever occur despite dose reduction ) Chemotherapy : See Disease Characteristics No great 3 prior chemotherapy regimens metastatic breast cancer either adjuvant neoadjuvant therapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent cytotoxic chemotherapy Endocrine therapy : Exogenous hormonal therapy stage IV disease and/or adjuvant therapy allow At least 3 week since prior hormonal therapy except : Patients highly unlikely withdrawal response cessation hormonal therapy ( e.g. , patient disease primarily resistant hormonal therapy , patient without prior partial response , stabilization disease last less 6 month ) Patients new extensive visceral metastasis Patients rapidly progressive symptomatic metastasis hormonal therapy Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No prior radiotherapy great 50 % bone marrow No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior major surgery recover No concurrent surgery Other : No concurrent anticancer treatment At least 28 day since prior investigational drug , include analgesic antiemetic No investigational drug 28 day study No drug induce inhibit CYP3A enzyme</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>